IP Library › Granted Patent US 11,633,348
Granted Patent B2
US 11,633,348 · App. 17/698,075 · Granted Apr 25, 2023

Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins

Inventors: Antoine Decrulle (Paris, FR); Xavier Duportet (Paris, FR)
Assignee: Eligo Bioscience
A61K8/99A61P17/00A61Q19/005A61Q19/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,633,348
App. No.
17/698,075
Granted
Apr 25, 2023
Kind
B2
Abstract

A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.

Claims (18)

1. A method for killing unfavorable bacteria on a healthy skin and/or mucosa of a subject, comprising applying on said healthy skin and/or mucosa of said subject an engineered postbiotic composition comprising a microbial lysate and lysostaphin, wherein said lysostaphin is obtained from bacteria heterologously expressing said lysostaphin,

wherein said microbial lysate and said lysostaphin have a synergistic effect in killing unfavorable bacteria on said healthy skin and/or mucosa of said subject.

2. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin are GRAS and/or probiotic bacteria.

3. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin have been obtained from bacteria isolated from a subject.

4. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin are Lactobacillus rhamnosus bacteria.

5. The method according to claim 1 , wherein said bacteria heterologously expressing said lysostaphin do not comprise any antibiotic resistance marker.

6. The method according to claim 1 , wherein said postbiotic composition comprises at least two different bacteriocins and/or endolysins.

7. The method according to claim 6 , wherein said at least two different bacteriocins and/or endolysins target the same bacterial species.

8. The method according to claim 6 , wherein said at least two different bacteriocins and/or endolysins target different bacterial species.

9. The method according to claim 1 , wherein said engineered postbiotic composition stimulates growth of at least one commensal bacterial species of the subject.

10. The method according to claim 9 , wherein said engineered postbiotic composition stimulates growth of at least one commensal bacterial species of the subject and said lysostaphin targets at least one unfavorable bacterial species.

11. The method according to claim 1 , for controlling and/or reducing body odor, wherein said engineered postbiotic composition is applied on the skin of the feet or the skin of the armpits.

12. The method according to claim 1 , wherein said engineered postbiotic composition is in the form of a cosmetic formulation for topical application.

13. A method for the care of sensitive, sensitized, fragile and/or weakened skin and/or mucosa, wherein an engineered postbiotic composition is applied on said sensitive, sensitized, fragile and/or weakened skin and/or mucosa,

wherein said engineered postbiotic composition comprises a microbial lysate and lysostaphin, wherein said lysostaphin is obtained from bacteria heterologously expressing said lysostaphin,

wherein said microbial lysate and said lysostaphin have a synergistic effect in killing unfavorable bacteria on said sensitive, sensitized, fragile and/or weakened skin and/or mucosa of said subject.

14. The method according to claim 13 , for the care of unaesthetic and/or unpleasant and/or uncomfortable manifestations of sensitive, sensitized, fragile and/or weakened skin and/or mucosa, wherein said engineered postbiotic is applied on the skin and/or mucosa of a subject with unaesthetic and/or unpleasant and/or uncomfortable manifestations of sensitive, sensitized, fragile and/or weakened skin and/or mucosa.

15. The method according to claim 14 , wherein the unaesthetic and/or unpleasant and/or uncomfortable manifestations of sensitive, sensitized, fragile and/or weakened skin and/or mucosa are chosen from the feeling of heat or warmth or tension, tingling, stinging, tightness, itching, pruritus, dry patches, erythema, redness and a mixture of these manifestations.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2022
From: DECRULLE, ANTOINE; DUPORTET, XAVIER
To: ELIGO BIOSCIENCE
Reel/Frame 059679/0353 →
Continuity (2)
Provisional Application 63163077 · Mar 19, 2021
Related Publication 20220296499A1 · Sep 22, 2022